Literature DB >> 26374685

Oversight on the borderline: Quality improvement and pragmatic research.

Jonathan A Finkelstein1, Andrew L Brickman2, Alexander Capron3, Daniel E Ford4, Adrijana Gombosev5, Sarah M Greene6, R Peter Iafrate7, Laura Kolaczkowski8, Sarah C Pallin9, Mark J Pletcher10, Karen L Staman11, Miguel A Vazquez12, Jeremy Sugarman13.   

Abstract

Pragmatic research that compares interventions to improve the organization and delivery of health care may overlap, in both goals and methods, with quality improvement activities. When activities have attributes of both research and quality improvement, confusion often arises about what ethical oversight is, or should be, required. For routine quality improvement, in which the delivery of health care is modified in minor ways that create only minimal risks, oversight by local clinical or administrative leaders utilizing institutional policies may be sufficient. However, additional consideration should be given to activities that go beyond routine, local quality improvement to first determine whether such non-routine activities constitute research or quality improvement and, in either case, to ensure that independent oversight will occur. This should promote rigor, transparency, and protection of patients' and clinicians' rights, well-being, and privacy in all such activities. Specifically, we recommend that (1) health care organizations should have systematic policies and processes for designating activities as routine quality improvement, non-routine quality improvement, or quality improvement research and determining what oversight each will receive. (2) Health care organizations should have formal and explicit oversight processes for non-routine quality improvement activities that may include input from institutional quality improvement experts, health services researchers, administrators, clinicians, patient representatives, and those experienced in the ethics review of health care activities. (3) Quality improvement research requires review by an institutional review board; for such review to be effective, institutional review boards should develop particular expertise in assessing quality improvement research. (4) Stakeholders should be included in the review of non-routine quality improvement and quality improvement-related research proposals. Only by doing so will we optimally leverage both pragmatic research on health care delivery and local implementation through quality improvement as complementary activities for improving health.
© The Author(s) 2015.

Entities:  

Keywords:  Quality improvement; ethics; health care operations; patient engagement; pragmatic clinical trials; research; stakeholder engagement

Mesh:

Year:  2015        PMID: 26374685      PMCID: PMC4699562          DOI: 10.1177/1740774515597682

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  19 in total

1.  The ethical review of health care quality improvement initiatives: findings from the field.

Authors:  Holly A Taylor; Peter J Pronovost; Ruth R Faden; Nancy E Kass; Jeremy Sugarman
Journal:  Issue Brief (Commonw Fund)       Date:  2010-08

2.  An instrument to differentiate between clinical research and quality improvement.

Authors:  Greg Ogrinc; William A Nelson; Susan M Adams; Ann E O'Hara
Journal:  IRB       Date:  2013 Sep-Oct

3.  Controversy and quality improvement: lingering questions about ethics, oversight, and patient safety research.

Authors:  Nancy Kass; Peter J Pronovost; Jeremy Sugarman; Christine A Goeschel; Lisa H Lubomski; Ruth Faden
Journal:  Jt Comm J Qual Patient Saf       Date:  2008-06

4.  OHRP and standard-of-care research.

Authors: 
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

5.  An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics.

Authors:  Ruth R Faden; Nancy E Kass; Steven N Goodman; Peter Pronovost; Sean Tunis; Tom L Beauchamp
Journal:  Hastings Cent Rep       Date:  2013 Jan-Feb       Impact factor: 2.683

6.  Ethics and regulatory complexities for pragmatic clinical trials.

Authors:  Jeremy Sugarman; Robert M Califf
Journal:  JAMA       Date:  2014-06-18       Impact factor: 56.272

7.  Determining when quality improvement initiatives should be considered research: proposed criteria and potential implications.

Authors:  D Casarett; J H Karlawish; J Sugarman
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

8.  Gatekeepers for pragmatic clinical trials.

Authors:  Danielle M Whicher; Jennifer E Miller; Kelly M Dunham; Steven Joffe
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

9.  The ethics of using quality improvement methods in health care.

Authors:  Joanne Lynn; Mary Ann Baily; Melissa Bottrell; Bruce Jennings; Robert J Levine; Frank Davidoff; David Casarett; Janet Corrigan; Ellen Fox; Matthew K Wynia; George J Agich; Margaret O'Kane; Theodore Speroff; Paul Schyve; Paul Batalden; Sean Tunis; Nancy Berlinger; Linda Cronenwett; J Michael Fitzmaurice; Nancy Neveloff Dubler; Brent James
Journal:  Ann Intern Med       Date:  2007-04-16       Impact factor: 25.391

Review 10.  Critical care checklists, the Keystone Project, and the Office for Human Research Protections: a case for streamlining the approval process in quality-improvement research.

Authors:  Richard H Savel; Evan B Goldstein; Michael A Gropper
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

View more
  19 in total

1.  Development of the Learning Health System Researcher Core Competencies.

Authors:  Christopher B Forrest; Francis D Chesley; Michelle L Tregear; Kamila B Mistry
Journal:  Health Serv Res       Date:  2017-08-04       Impact factor: 3.402

2.  Predicting preventable hospital readmissions with causal machine learning.

Authors:  Ben J Marafino; Alejandro Schuler; Vincent X Liu; Gabriel J Escobar; Mike Baiocchi
Journal:  Health Serv Res       Date:  2020-10-30       Impact factor: 3.402

3.  Exploring the ethical and regulatory issues in pragmatic clinical trials.

Authors:  Robert M Califf; Jeremy Sugarman
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

4.  Responding to signals of mental and behavioral health risk in pragmatic clinical trials: Ethical obligations in a healthcare ecosystem.

Authors:  Joseph Ali; Stephanie R Morain; P Pearl O'Rourke; Benjamin Wilfond; Emily C O'Brien; Christina K Zigler; Karen L Staman; Kevin P Weinfurt; Jeremy Sugarman
Journal:  Contemp Clin Trials       Date:  2022-01-05       Impact factor: 2.226

5.  Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials.

Authors:  Carole A Federico; Patrick J Heagerty; John Lantos; Pearl O'Rourke; Vasiliki Rahimzadeh; Jeremy Sugarman; Kevin Weinfurt; David Wendler; Benjamin S Wilfond; David Magnus
Journal:  Contemp Clin Trials       Date:  2022-02-15       Impact factor: 2.261

6.  Learning health care systems: Highly needed but challenging.

Authors:  Roel H P Wouters; Rieke van der Graaf; Emile E Voest; Annelien L Bredenoord
Journal:  Learn Health Syst       Date:  2020-01-13

7.  Ethics and Collateral Findings in Pragmatic Clinical Trials.

Authors:  Stephanie R Morain; Kevin Weinfurt; Juli Bollinger; Gail Geller; Debra Jh Mathews; Jeremy Sugarman
Journal:  Am J Bioeth       Date:  2020-01       Impact factor: 11.229

8.  Aiming to Improve Readmissions Through InteGrated Hospital Transitions (AIRTIGHT): study protocol for a randomized controlled trial.

Authors:  Andrew McWilliams; Jason Roberge; Charity G Moore; Avery Ashby; Whitney Rossman; Stephanie Murphy; Stephannie McCall; Ryan Brown; Shannon Carpenter; Scott Rissmiller; Scott Furney
Journal:  Trials       Date:  2016-12-19       Impact factor: 2.279

9.  Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory.

Authors:  Kevin P Weinfurt; Adrian F Hernandez; Gloria D Coronado; Lynn L DeBar; Laura M Dember; Beverly B Green; Patrick J Heagerty; Susan S Huang; Kathryn T James; Jeffrey G Jarvik; Eric B Larson; Vincent Mor; Richard Platt; Gary E Rosenthal; Edward J Septimus; Gregory E Simon; Karen L Staman; Jeremy Sugarman; Miguel Vazquez; Douglas Zatzick; Lesley H Curtis
Journal:  BMC Med Res Methodol       Date:  2017-09-18       Impact factor: 4.615

Review 10.  Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation.

Authors:  Cory E Goldstein; Charles Weijer; Jamie C Brehaut; Dean A Fergusson; Jeremy M Grimshaw; Austin R Horn; Monica Taljaard
Journal:  BMC Med Ethics       Date:  2018-02-27       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.